Lecheng introduces world's first KRAS protein inhibitor
Lumakras (Sotorasib), the world's first kirsten rat sarcoma (KRAS) protein inhibitor for lung cancer, is now available in Lecheng.
Lumakras (Sotorasib), the world's first kirsten rat sarcoma (KRAS) protein inhibitor for lung cancer, is now available in Hainan Boao Lecheng International Medical Tourism Pilot Zone, local media outlets reported on Aug 17.
Sotorasib was approved by the US Food and Drug Administration in May to treat adults who have non-small cell lung cancer (NSCLC), and especially for those who have tumors with a genetic mutation called KRAS G12C.
The medicine is developed by the US-based Amgen, one of the world's leading biotechnology companies. BeiGene has been granted the exclusive commercial rights of Lumakras in China.
The KRAS G12C mutation is the most common genetic abnormality associated with NSCLC. Nearly 13 percent of the patients with lung cancer in western countries will develop this mutation and the incidence rate of the mutation among Chinese patients is around 2.8 percent to 5 percent.